{"organizations": [], "uuid": "daa144ffed6e0bd9acb26ff27ab6c6d8f3aea087", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 12, "shares": 12, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-mylan-nl-revance/mylan-teams-up-with-revance-on-biosimilar-for-botox-idUSKCN1GC35Z", "country": "US", "domain_rank": 408, "title": "CORRECTED-Mylan teams up with Revance on biosimilar for Botox", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T00:36:00.000+02:00", "replies_count": 0, "uuid": "daa144ffed6e0bd9acb26ff27ab6c6d8f3aea087"}, "author": "", "url": "https://www.reuters.com/article/us-mylan-nl-revance/mylan-teams-up-with-revance-on-biosimilar-for-botox-idUSKCN1GC35Z", "ord_in_thread": 0, "title": "CORRECTED-Mylan teams up with Revance on biosimilar for Botox", "locations": [], "entities": {"persons": [{"name": "susan thomas", "sentiment": "none"}, {"name": "revance", "sentiment": "none"}, {"name": "michael erman", "sentiment": "none"}], "locations": [{"name": "new york", "sentiment": "none"}, {"name": "revance", "sentiment": "none"}], "organizations": [{"name": "mylan", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "revance therapeutics inc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "mylan nv", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK (Reuters) - Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.\nThe deal includes an upfront payment of $25 million to Revance​, Mylan said.\nRevance’s own rival to Botox is not yet approved by the U.S. Food and Drug Administration. Revance reported positive Phase III data for its longer-lasting wrinkle treatment in December and said then that it planned to launch the drug in 2020, pending FDA approval.\n(Corrects third paragraph to show that Phase III trial is for a different rival drug.)\nReporting by Michael Erman; Editing by Susan Thomas\n ", "external_links": [], "published": "2018-03-01T00:36:00.000+02:00", "crawled": "2018-03-01T00:53:44.045+02:00", "highlightTitle": ""}